


**Synonym**

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

**Source**

Biotinylated Cynomolgus / Rhesus macaque LRRC15, His,Avitag(LR5-C82E7) is expressed from human 293 cells (HEK293). It contains AA Tyr 22 - Gly 538 (Accession # [A0A2K5UKB6-1](#) ).

**Molecular Characterization**

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 61.6 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

**Labeling**

*Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.*

**Protein Ratio**

Passed as determined by the HABA assay / binding ELISA.

**Endotoxin**

Less than 1.0 EU per µg by the LAL method.

**Purity**

>95% as determined by SDS-PAGE.

**Formulation**

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*


**Storage**

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

*Please avoid repeated freeze-thaw cycles.*


This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

**SDS-PAGE**

Biotinylated Cynomolgus / Rhesus macaque LRRC15, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

**Bioactivity-ELISA**



Immobilized Biotinylated Cynomolgus / Rhesus macaque LRRC15, His,Avitag (Cat. No. LR5-C82E7) at 1 µg/mL (100 µL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 µg/well) plate can bind Samrotamab with a linear range of 0.1-2 ng/mL (QC tested).

## Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

## Clinical and Translational Updates

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.